Suppr超能文献

通过抑制CBP/EP300溴结构域对调节性T细胞进行调控

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.

作者信息

Ghosh Srimoyee, Taylor Alexander, Chin Melissa, Huang Hon-Ren, Conery Andrew R, Mertz Jennifer A, Salmeron Andres, Dakle Pranal J, Mele Deanna, Cote Alexandre, Jayaram Hari, Setser Jeremy W, Poy Florence, Hatzivassiliou Georgia, DeAlmeida-Nagata Denise, Sandy Peter, Hatton Charlie, Romero F Anthony, Chiang Eugene, Reimer Thornik, Crawford Terry, Pardo Eneida, Watson Venita G, Tsui Vickie, Cochran Andrea G, Zawadzke Laura, Harmange Jean-Christophe, Audia James E, Bryant Barbara M, Cummings Richard T, Magnuson Steven R, Grogan Jane L, Bellon Steve F, Albrecht Brian K, Sims Robert J, Lora Jose M

机构信息

From the Constellation Pharmaceuticals, Inc., Massachusetts 02142 and.

Genentech, Inc., South San Francisco, California 94080.

出版信息

J Biol Chem. 2016 Jun 17;291(25):13014-27. doi: 10.1074/jbc.M115.708560. Epub 2016 Apr 7.

Abstract

Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control. Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription. Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chemical probes serves as a powerful means for understanding biological processes regulated by these chromatin adaptors. Here we describe the discovery and characterization of potent and selective small molecule inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays. We use these tools to demonstrate a critical role for CREBBP/EP300 bromodomains in regulatory T cell biology. Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, our data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small molecule-based approach for cancer immunotherapy.

摘要

组蛋白的共价修饰是真核生物中基因表达调控的基本机制,而组蛋白修饰的解读是表观遗传控制的一个基本特征。溴结构域是与乙酰化组蛋白相互作用的特殊结合模块,将染色质识别与基因转录联系起来。由于它们能够以结构域特异性的方式发挥作用,用化学探针选择性破坏溴结构域与乙酰化组蛋白的相互作用是理解这些染色质衔接蛋白所调控的生物学过程的有力手段。在此,我们描述了用于CREBBP/EP300溴结构域的强效且选择性小分子抑制剂的发现与表征,这些抑制剂在细胞试验中与它们的靶点结合。我们使用这些工具来证明CREBBP/EP300溴结构域在调节性T细胞生物学中的关键作用。由于调节性T细胞向肿瘤的募集是癌细胞免疫逃逸的主要机制,我们的数据凸显了抑制CREBBP/EP300溴结构域作为一种基于小分子的新型癌症免疫治疗方法的重要性。

相似文献

1
Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
J Biol Chem. 2016 Jun 17;291(25):13014-27. doi: 10.1074/jbc.M115.708560. Epub 2016 Apr 7.
2
Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
J Med Chem. 2021 Jul 22;64(14):10102-10123. doi: 10.1021/acs.jmedchem.1c00348. Epub 2021 Jul 13.
3
CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Mol Cancer Res. 2019 Mar;17(3):720-730. doi: 10.1158/1541-7786.MCR-18-0719. Epub 2019 Jan 3.
4
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Epigenetics Chromatin. 2018 Jun 8;11(1):30. doi: 10.1186/s13072-018-0197-x.
5
Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Nat Chem Biol. 2019 May;15(5):519-528. doi: 10.1038/s41589-019-0264-z. Epub 2019 Apr 8.
6
Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Mol Cancer Ther. 2018 Dec;17(12):2543-2550. doi: 10.1158/1535-7163.MCT-18-0511. Epub 2018 Sep 28.
7
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
J Am Chem Soc. 2014 Jul 2;136(26):9308-19. doi: 10.1021/ja412434f. Epub 2014 Jun 19.
8
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.
Cancer Res. 2019 Aug 1;79(15):3916-3927. doi: 10.1158/0008-5472.CAN-18-3622. Epub 2019 Jun 10.
9
Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.
J Med Chem. 2017 Jul 13;60(13):5349-5363. doi: 10.1021/acs.jmedchem.6b01839. Epub 2017 May 12.
10
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
J Med Chem. 2016 Feb 25;59(4):1271-98. doi: 10.1021/acs.jmedchem.5b01514. Epub 2015 Dec 1.

引用本文的文献

2
The epigenetic hallmarks of immune cells in cancer.
Mol Cancer. 2025 Mar 5;24(1):66. doi: 10.1186/s12943-025-02255-4.
3
Dysregulation of the p300/CBP histone acetyltransferases in human cancer.
Epigenomics. 2025 Feb;17(3):193-208. doi: 10.1080/17501911.2024.2447807. Epub 2024 Dec 30.
5
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.
J Immunother Cancer. 2024 Nov 7;12(11):e010145. doi: 10.1136/jitc-2024-010145.
9
CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders.
Biomedicines. 2024 Jun 18;12(6):1344. doi: 10.3390/biomedicines12061344.
10
Discovery of an EP300 Inhibitor using Structure-based Virtual Screening and Bioactivity Evaluation.
Curr Pharm Des. 2024;30(25):1985-1994. doi: 10.2174/0113816128298051240529113313.

本文引用的文献

1
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
ACS Med Chem Lett. 2016 Mar 15;7(5):531-6. doi: 10.1021/acsmedchemlett.6b00075. eCollection 2016 May 12.
3
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Cancer Res. 2015 Dec 1;75(23):5106-5119. doi: 10.1158/0008-5472.CAN-15-0236. Epub 2015 Nov 9.
4
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73. doi: 10.1073/pnas.1501956112. Epub 2015 Aug 10.
5
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.
Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.
6
Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function.
Mol Cell Biol. 2014 Nov;34(21):3993-4007. doi: 10.1128/MCB.00919-14. Epub 2014 Aug 25.
7
Tim-3: an emerging target in the cancer immunotherapy landscape.
Cancer Immunol Res. 2014 May;2(5):393-8. doi: 10.1158/2326-6066.CIR-14-0039.
8
The role of bromodomain proteins in regulating gene expression.
Genes (Basel). 2012 May 29;3(2):320-43. doi: 10.3390/genes3020320.
9
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Nat Chem Biol. 2014 Apr;10(4):305-12. doi: 10.1038/nchembio.1471. Epub 2014 Mar 2.
10
Regulatory T cells in cancer immunotherapy.
Curr Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验